Results 81 to 90 of about 22,643,381 (355)
Queen Victoria and The Royal Disease [PDF]
, 2018 Queen Victoria, Queen of England and Ireland and Empress of India, is the second longest ruling monarch of England, she sat on the throne for sixty –three years and was so crucial to the formation of England that there is a whole era names after her, The
Mullen, Madeline
core +1 more source
Spontaneous Iliopsoas Hematoma following Microvascular Free Tissue Transfer. [PDF]
, 2017 Spontaneous hematoma within the iliopsoas muscle (SIH) is a rare complication most commonly seen in coagulopathic patients. Often, patients undergoing microvascular free tissue transfer are anticoagulated for anastomotic patency.
Alemi, A Sean +5 more
core +2 more sources
Otogenic Sinus Thrombosis and Hemophilia: A Clinical Case
Кубанский научный медицинский вестник, 2023 Background. Patients with hemophilia are protected from thrombosis by a deficiency of one of coagulation factors, therefore thrombotic complications are rare in them.
I. M. Veshkurtseva +5 more
doaj +1 more source
Blood, 2019 Results from the main parts (24 weeks) of two concizumab phase 2 trials are presented: explorer4 (NCT03196284) in hemophilia A (HA) or B (HB) with inhibitors (HAwI/HBwI); explorer5 (NCT03196297) in HA without inhibitors.
A. Shapiro +14 more
semanticscholar +1 more source
Model‐Informed Drug Development Applications and Opportunities in mRNA‐LNP Therapeutics
Clinical Pharmacology &Therapeutics, EarlyView.The utilization of lipid nanoparticles (LNP) for encapsulating mRNA has revolutionized the field of therapeutics, enabling the rapid development of COVID‐19 vaccines and cancer vaccines. However, the clinical development of mRNA‐LNP therapeutics faces numerous challenges due to their complex mechanisms of action and limited clinical experience.
Jiawei Zhou +6 more
wiley +1 more source
Haemophilia A: pharmacoeconomic review of prophylaxis treatment versus on-demand [PDF]
, 2015 Objectives. Haemophilia A is a congenital disorder of coagulation that mainly affects males and causes a considerable use of resources, especially when hemophilic patients are treated with prophylaxis.
BOCCIA, Antonio +4 more
core +2 more sources
New therapies for von Willebrand disease
Blood Advances, 2019 : The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C ...
Pier Mannuccio Mannucci
doaj
Clinical Pharmacology &Therapeutics, EarlyView.In hemophilia B, pharmacokinetic (PK)‐guided dosing of extended half‐life factor IX (EHL‐FIX) concentrates can secure targeted FIX exposure. Target FIX activity levels in plasma should be individually set primarily taking bleeding tendency into account, alongside the presence of target joints, physical activity, and preferred dosing schedules. In other
Sjoerd F. Koopman +4 more
wiley +1 more source
, 2017 Von Willebrand Disease (VWD) is a blood clotting disorder characterized by low levels of the Von Willebrand Factor (VWF) in the blood. VWF is functions to bind platelets and promote clotting of the blood when vascular injury occurs.
Misla David, Ramon
core +2 more sources
Emicizumab in the treatment of hemophilia A [PDF]
Acta Stomatologica Naissi, 2020 Introduction: Despite substantial advances in the treatment of Hemophilia A with the use of concentrated factor VIII preparations during recent decades, bleeding episodes still occur from time to time.
Tijanić Ivan R. +3 more
doaj